Full-Time
Global Development Lead
Late-Stage Oncology Clinical Development, Non MD
Posted on 10/25/2024
Pfizer
10,001+ employees
Biopharmaceutical company develops medicines and vaccines
Compensation Overview
$226.2k - $377k/yr
Cambridge, MA, USA + 6 more
More locations: San Francisco, CA, USA | Bothell, WA, USA | Phoenixville, PA, USA | La Jolla, San Diego, CA, USA | Groton, CT, USA | New York, NY, USA
Relocation assistance may be available based on business needs and/or eligibility.
Relocation assistance may be available based on business needs and/or eligibility.
Relocation assistance may be available based on business needs and/or eligibility.
 Medical, Clinical & Veterinary (2) |
|---|
| , |
- Advanced degree with relevant clinical/industry experience (typically 4+ years).
- 15+ years industry experience
- 5+ years of experience leading diverse teams
- Prior management responsibilities of medical directors or clinical scientists
- Lead product specific Global Development Teams
- Serves as the subject matter expert on clinical issues
- Work across the organization and on the cross-functional Global Development Team to lead, develop and execute the clinical development plan of TIVDAK in cervical cancer and another new molecular entity entering late-stage clinical development.
- Endorses clinical decisions in advance of GPT, senior management reviews or governance bodies
- Provide oversight and management responsibilities of medical director(s)
- Accountable for the clinical development strategy, trial design, execution, and delivery of trial results
- Accountable for integrating regulatory, statistical and other internal and external stakeholder input into study designs
- Serves as primary interface with Development Review Committee
- Oversee the development and management of clinical protocols and amendments, investigator brochures, and clinical study reports
- Oversee the evaluation, interpretation, reporting and presentation of study data
- Accountable with safety for clinical evaluations and safety decisions
- Accountable with clinical pharmacology for defining and identifying optimal dose and schedule selection
- Accountable with regulatory for health authority interactions
- May participate in evaluating business development opportunities
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
Simplify's Take
What believers are saying
- Vyndamax exclusivity through mid-2031 protects a $3.8 billion U.S. revenue bridge.
- Phase 3 pneumococcal programs can extend Pfizer’s vaccine franchise with higher-valence products.
- Expanded HYMPAVZI and Rigel’s VEPPANU deal add near-term rare-disease and oncology upside.
What critics are saying
- Eliquis, Ibrance, and Xeljanz face patent cliffs from 2026 through 2030.
- COVID product sales collapsed from $56.7 billion in 2022 to about $5 billion in 2026.
- GLP-1 setbacks leave Pfizer without a clear obesity growth driver before 2028.
What makes Pfizer unique
- Pfizer spans vaccines, oncology, rare diseases, and internal medicine across 125+ countries.
- Its Seagen acquisition strengthens antibody-drug conjugates and expands oncology depth.
- HYMPAVZI and VEPPANU show a partnership-heavy model for specialty pipeline monetization.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Pfizer who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 2%ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich
Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.
Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.
Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.
Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.